Suppressor Cell–Depleting Immunotherapy With Denileukin Diftitox is an Effective Host-Directed Therapy for Tuberculosis

Versatile myeloid cell subsets contribute to tuberculosis-associated inflammation

(2015) Anca Dorhoi et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Lung-Residing Myeloid-derived Suppressors Display Dual Functionality in Murine Pulmonary Tuberculosis

(2014) Julia K. Knaul et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Acceleration of Tuberculosis Treatment by Adjunctive Therapy with Verapamil as an Efflux Inhibitor

(2013) Shashank Gupta et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Pathogen-Specific Treg Cells Expand Early during Mycobacterium tuberculosis Infection but Are Later Eliminated in Response to Interleukin-12

(2013) Shahin Shafiani et al.   IMMUNITY

A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study

(2013) Francine M. Foss et al.   LEUKEMIA & LYMPHOMA

Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma

(2011) Sucheta Telang et al.   BMC CANCER

Regulatory T Cells Stimulate B7-H1 Expression in Myeloid-Derived Suppressor Cells in ret Melanomas

(2011) Taku Fujimura et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Therapeutic Enhancement of Protective Immunity during Experimental Leishmaniasis

(2011) Senad Divanovic et al.   PLoS Neglected Tropical Diseases

A Pilot Study of Denileukin Diftitox (DD) in Combination With High-dose Interleukin-2 (IL-2) for Patients With Metastatic Renal Cell Carcinoma (RCC)

(2010) Elizabeth Atchison et al.   JOURNAL OF IMMUNOTHERAPY